Evaluation of a hand-held far-ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens
© Nerandzic et al.; licensee BioMed Central Ltd 2012
Received: 29 November 2011
Accepted: 16 May 2012
Published: 16 May 2012
Environmental surfaces play an important role in transmission of healthcare-associated pathogens. There is a need for new disinfection methods that are effective against Clostridium difficile spores, but also safe and rapid. The Sterilray™ Disinfection Wand device is a hand-held room decontamination technology that utilizes far-ultraviolet radiation (185-230 nm) to kill pathogens.
We examined the efficacy of disinfection using the Sterilray device in the laboratory, in rooms of hospitalized patients, and on surfaces outside of patient rooms (i.e. keyboards and portable medical equipment). Cultures for C. difficile, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) were collected from commonly-touched surfaces before and after use of the Sterilray device.
On inoculated surfaces in the laboratory, application of the Sterilray device at a radiant dose of 100 mJ/cm2 for ~ 5 seconds consistently reduced recovery of C. difficile spores by 4.4 CFU log10, MRSA by 5.4 log10CFU and of VRE by 6.9 log10CFU. A >3 log10 reduction of MRSA and VRE was achieved in ~2 seconds at a lower radiant dose, but killing of C. difficile spores was significantly reduced. On keyboards and portable medical equipment that were inoculated with C. difficile spores, application of the Sterilray device at a radiant dose of 100 mJ/cm2 for ~ 5 seconds reduced contamination by 3.2 log10CFU. However, the presence of organic material reduced the lethal effect of the far-UV radiation. In hospital rooms that were not pre-cleaned, disinfection with the Sterilray device significantly reduced the frequency of positive C. difficile and MRSA cultures (P =0.007).
The Sterilray™ Disinfection Wand is a novel environmental disinfection technology that rapidly kills C. difficile spores and other healthcare-associated pathogens on surfaces. However, the presence of organic matter reduces the efficacy of far-UV radiation, possibly explaining the more modest results observed on surfaces in hospital rooms that were not pre-cleaned.
Environmental surfaces play an important role in transmission of healthcare-associated pathogens such as Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) [1–6]. In addition to high-touch sites inside patient rooms, contamination of portable equipment has been implicated as a source of pathogen transmission . C. difficile is particularly challenging for infection control because it produces spores that are resistant to killing by most disinfectants . Because standard cleaning methods are often suboptimal, there is a need for new environmental disinfection methods that are effective against a wide range of pathogens including C. difficile spores [5, 6, 9, 10].
Several recent studies have demonstrated that an automated ultraviolet-C (UV-C) device may be effective as an adjunctive method for disinfection of healthcare-associated pathogens including C. difficile in patient rooms . While the UV-C device has some potential advantages over other disinfection strategies, cycles that are effective for killing of C. difficile spores require approximately 45 minutes and patients cannot be in the room during use of the device. The mechanism of killing of microorganisms by UV-C (230–280 nm) is primarily due to inactivation of DNA through absorption of photons [12–15]. The far-UV radiation spectrum (185–230 nm) has more photon energy than UV-C, and could potentially achieve lethal doses of radiation in less time . In addition to inactivation of DNA, far-UV's increased photon energy is absorbed by peptide and disulfide bonds, which breaks the bonds and causes irreparable damage . However, limited data are available regarding the effectiveness of far-UV in killing healthcare-associated pathogens and it is unclear if far-UV will be effective or practical to use in healthcare settings.
The Sterilray™ Disinfection Wand (Healthy Environment Innovations, Inc., Dover, New Hampshire) is a mobile, hand-held device that utilizes far-UV radiation to kill pathogens. The far-UV administered by the Sterilray device is localized under the wand and it has been proposed that it may be used to treat surfaces in rooms occupied by patients. Here, we examined the effectiveness of the Sterilray device for killing pathogens in the laboratory and in rooms of hospitalized patients. We additionally assessed the use of the Sterilray device for reducing levels of C. difficile spores on computer keyboards and portable medical equipment.
Materials and methods
The study protocol was approved by the Veterans Affairs Medical Center's research and development committee. There was no direct contact with human subjects in this study, therefore the hospital's institutional review board exempted the study protocol from review.
The Cleveland Veterans Affairs Medical Center is a 265-bed acute care hospital. At the time of the study, active surveillance for MRSA carriage was performed and colonized or infected patients were placed in contact precautions. Patients with CDI were placed in contact precautions until they completed treatment and diarrhea resolved. No active surveillance was performed for VRE, and VRE-colonized or infected patients were not placed in contact precautions.
C. difficile, MRSA, and VRE strains
One C. difficile strain from the American Type Culture Collection (ATCC) and 3 strains cultured from patients with CDI in Cleveland were studied. ATCC 43593 is a non-toxigenic strain of C.difficile from serogroup B. VA 17 is a restriction endonuclease analysis (REA) type BI strain and VA 11 and VA 9 are REA type J strains. Two clinical MRSA strains were studied, including one pulsed-field gel electrophoresis type USA300 (community-associated) strain and one USA800 strain (hospital-associated). Two VRE strains were studied, including one VanA-type isolate (C37) and one VanB-type isolate (C68).
Preparation of C. difficile spores, MRSA, and VRE strains
C. difficile spores were prepared by growth on Duncan and Strong agar medium as previously described [18, 19]. Spores were stored at 4°C in sterile distilled water until use. Prior to testing, spore preps were confirmed by phase contrast microscopy and malachite green staining to be > 99% dormant, bright-phase spores. MRSA and VRE strains were streaked for isolation and incubated for 24 hours on blood agar plates. Several colonies from overnight cultures were suspended in phosphate-buffered saline (PBS) or nutrient broth with 10 mg/ml bovine serum albumin. Colony forming units (CFU) were enumerated by serially diluting and plating suspensions on selective agar as described below in Microbiology.
The Sterilray device
Reduction of pathogens by the Sterilray device
Initial experiments were conducted to examine the efficacy of the Sterilray device for killing of C. difficile, MRSA and VRE in the laboratory. Organisms were suspended in sterile phosphate buffered saline or Brain-heart infusion broth containing 10 mg/mL bovine serum albumin (simulated organic load). Nine droplets (twenty μL) of each organism (106 to 108 CFU) were inoculated onto the cover of a sterile, plastic Petri dish. To assess the lethal effects of increasing doses of far-UV and to determine the effects of concomitant production of ozone at the high power setting, the droplets were either subjected to low power ("smooth" setting) or high power ("deodorize" setting with ozone) irradiation at a radiant dose of 10, 20, 30, 50 or 100 mJ/cm2 with the Sterilray device or left untreated (i.e. positive controls). Radiant dose was measured by placing a radiometer (International Light, Inc., Newburyport, MA, USA) next to the samples during treatment with Sterilray. After the organisms were treated, the droplets were collected by tipping the Petri dish cover and collecting the drops into a tube. The organisms were enumerated by serially diluting and plating suspensions. Experiments were repeated three times.
Additional experiments were performed to test the efficacy of the Sterilray device for killing spores in the presence of naturally-occurring organic material. Stool samples, containing vegetative and spore forms of C.difficile, were obtained from two patients with active CDI and 10 microliter aliquots (103-104 CFU) were spread in thin layers onto 2 cm2 areas of glass slides. Previously it has been demonstrated that vegetative forms of C.difficile die rapidly upon desiccation in room air . Therefore, to confirm that only spores remained, the slides were allowed to desiccate in room air for an hour to eliminate vegetative C.difficile, then subjected to high power irradiation at a radiant dose of 100 mJ/cm2 with the Sterilray device or left untreated. The slides were sampled with sterile swabs (BD BBL™ CultureSwab™, Becton Dickinson, Cockeysville, MD) pre-moistened with saline, transferred into an anaerobic chamber, spread onto pre-reduced C. difficile selective media and incubated as described previously. Colony forming units were enumerated using Fotodyne's TotalLab Quant Analysis software (Fotodyne Inc., Hartland, Wisconsin) and treated versus untreated samples were compared.
Reduction of C. difficile on keyboards and portable medical equipment
Experiments were performed to assess the use of the Sterilray device for reduction of C. difficile spores artificially applied to keyboards and portable medical equipment (i.e. stethoscopes, pulse oximeters, blood pressure cuffs). Ten microliters of ATCC 43593 C. difficile spores (104 to 105 CFU) were inoculated onto a 1 cm2 area of each surface. After air drying, each object was subjected to a high power radiant dose of 100 (mJ/cm2) for ~5 seconds or left untreated (positive control). The inoculated surfaces were then sampled with sterile swabs (BD BBL™ CultureSwab™, Becton Dickinson, Cockeysville, MD) pre-moistened with saline, transferred into an anaerobic chamber, spread onto pre-reduced C. difficile selective media and incubated as described previously. Colony forming units were enumerated using Fotodyne's TotalLab Quant Analysis software (Fotodyne Inc., Hartland, Wisconsin) and treated versus untreated samples were compared. Experiments were performed in triplicate.
Disinfection of surfaces in hospital rooms
The efficacy of the Sterilray device was assessed in rooms of discharged patients that had not yet been cleaned by housekeeping. Organisms were not inoculated onto surfaces for these experiments. Sterile swabs (BD BBL™ CultureSwab™, Becton Dickinson, Cockeysville, MD) pre-moistened with saline were used to collect cultures from the call light, bedside table, telephone, and bed rail before and after use of the Sterilray device on high power at a radiant dose of 100 mJ/cm2 for ~ 5 seconds. MRSA cultures were collected from MRSA isolation rooms, whereas VRE and C. difficile cultures were collected from rooms that housed patients with CDI and from non-CDI rooms. The device was held 10 cm above each surface during disinfection. For the bed rail and table, 5 x 20 cm areas were cultured before Sterilray disinfection and adjacent areas of the same surface area were cultured after disinfection; for the call button and telephone, half of the entire surface area (~5 x 10 cm for the call button and ~5 x 20 cm for the telephone) was cultured before Sterilray disinfection and the other half was cultured after disinfection.
For VRE, MRSA, and C. difficile cultures, selective media included Enterococcosel agar (Becton Dickinson, Cockeysville, MD) containing 20 μg/mL of vancomycin, CHROMagar (Becton Dickinson) containing 6 μg/mL of cefoxitin, and cycloserine-cefoxitin-brucella agar containing 0.1% taurocholic acid and lysozyme 5 mg/mL (CDBA), respectively . Plates were incubated at 37°C for 48 hours. VRE and MRSA colonies with unique morphology were subjected to identification and susceptibility testing in accordance with Clinical Laboratories Standards Institute guidelines . C. difficile was confirmed on the basis of typical odor and appearance of colonies and by a positive reaction using C. difficile latex agglutination (Microgen Bioproducts, Camberly, UK).
Data were analyzed using STATA 9.0 (StataCorp, College Station, TX). Continuous data were analyzed using paired t tests and categorical data were assessed using Fisher’s exact test.
Reduction of pathogens by the Sterilray device
When pathogens were suspended in brain-heart infusion broth with 10 mg/ml bovine serum albumin the lethal effects of the Sterilray device were completely eliminated (i.e., no killing of pathogens was observed in the presence of the heavy simulated organic load). C. difficile spores in a fecal matrix were reduced by ~1 log10CFU after treatment with the Sterilray device at a radiant dose of 100 mJ/cm2 for ~5 seconds.
Reduction of C. difficile on keyboards and portable medical equipment
On keyboards and portable medical equipment that were inoculated with C.difficile spores suspended in sterile water, application of the Sterilray device at a radiant dose of 100 mJ/cm2 for ~ 5 seconds consistently reduced contamination by 3.2 log10CFU (P < 0.001).
Disinfection in hospital rooms
Recovery of Clostridium difficile , vancomycin-resistant Enterococcus , and methicillin-resistant Staphylococcus aureus (MRSA) from surfaces in hospital rooms before and after use of the Sterilray device
Sites positive (%)
Mean colony forming units recovered (range)
The Sterilray far-UV device consistently and rapidly killed C. difficile spores, MRSA, and VRE in the absence of organic material (i.e. artificial inoculation in the laboratory setting and on keyboards and portable equipment). C.difficile spores were reduced by 4.4 log10CFU in ~5 seconds, while MRSA and VRE showed similar reductions in ~2 seconds. However, the lethal effects of the device were reduced when spores were in the presence of stool and completely eliminated in the presence of a heavy organic load (i.e., nutrient broth and 10 mg/ml bovine serum albumin). This phenomenon may explain the fact that the Sterilray device had relatively modest effects in reducing levels of pathogens on surfaces in hospital rooms that had not previously been cleaned. These results suggest that the Sterilray device could be used as an adjunct to routine cleaning measures in healthcare facilities, but that it will be most effective in settings where organic load is minimized.
The Sterilray device has some potential advantages over other disinfection technologies. First, it provides very rapid killing of pathogens. The Sterilray device kills C. difficile spores on surfaces in seconds, whereas UV-C room disinfection devices may require 45 minutes and hydrogen peroxide vapor or mist systems may require hours for setup and disinfection of a hospital room [11, 22, 23]. Second, according to the manufacturer, the Sterilray device can safely be used when patients are in the room. Third, there were no apparent adverse effects on surfaces when the Sterilray device was used repeatedly ( >10 applications), whereas sporicidal disinfectants such as sodium hypochlorite may be corrosive to materials. Fourth, the Sterilray is portable and can be transported easily from room to room or to areas where portable equipment and keyboards are located. Moreover, the device could potentially fill a niche for reducing pathogens on objects that are not easily or frequently disinfected (i.e. plastic/vinyl curtains, stethoscopes, shoes, patient belongings, etc.). Finally, the Sterilray device is relatively easy to use and does not require a dedicated staff to operate. Therefore, after the initial purchase of the device (~ $30,000), the cost of operating and maintaining the Sterilray device is minimal.
The Sterilray device does have some potential limitations. Far-UV irradiation does not penetrate porous fabrics. Therefore, it will not be effective for disinfecting items such as bedding, cloth curtains, or upholstery. Additionally, the presence of organic material on surfaces will reduce the effectiveness of far-UV radiation. Further studies are needed to determine if pre-cleaning surfaces with a detergent product will improve the effectiveness of the Sterilray device. Our assessment was limited to research workers rather than housekeeping staff. Additional studies are needed to evaluate whether the far-UV device can easily be incorporated into house-keeping practices. The device is not automated and correct usage by the operator with regard to application time and distance from the surfaces is required. Development of a far-UV box for disinfection of portable equipment and devices is in progress and would eliminate the potential for operator error by providing standardized exposure to far-UV.
Our study has some limitations. The use of swabs and direct plating to quantify the concentrations of bacteria on surfaces is imprecise at higher concentrations. In addition, recovery and release of bacteria from swabs is less than 100% and therefore we may not have detected lower levels of bacteria on surfaces. However, methods were standardized for processing all samples so any limitations in the methodology would be equally shared by baseline and experimental groups. Environmental surfaces collected with the use of swabs were not blinded to lab personnel, therefore there is the additional possibility of sampling bias in this study. However, for simplicity purposes, each surface was split into half, and pre and post-disinfection surfaces were not varied in this study in order to avoid errors when culturing and processing the samples.
The Sterilray far-UV Disinfection Wand is a novel environmental disinfection technology that rapidly kills C. difficile spores and other healthcare-associated pathogens on surfaces. However, the presence of organic matter decreases the efficacy of far-UV radiation, and may limit the utility of this technology in healthcare settings. Further studies are needed to determine if the device may be useful as an adjunct to standard environmental cleaning measures in healthcare facilities.
This work was supported by a Merit Review grant from the Department of Veterans Affairs to CJD. We thank Healthy Environment Innovations, Dover, New Hampshire for providing the Sterilray device used in this study. Healthy Environment Innovations did not provide funding for the study and did not contribute to the study design, writing or editing of the manuscript.
- Goodman ER, Platt R, Bass R, Onderdonk AB, Yokoe DS, Huang SS: Impact of an environmental cleaning intervention on the presence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci on surfaces in intensive care unit rooms. Infect Control Hosp Epidemiol. 2008, 29: 593-599. 10.1086/588566.View ArticlePubMedPubMed CentralGoogle Scholar
- Boyce JM, Pittet D: Guideline for hand hygiene in health-care settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol. 2002, 23 (Suppl): S3-S40.View ArticlePubMedGoogle Scholar
- Bhalla A, Pultz NJ, Gries DM, Ray AJ, Eckstein EC, Aron DC, Donskey CJ: Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. Infect Control Hosp Epidemiol. 2004, 25: 164-167. 10.1086/502369.View ArticlePubMedGoogle Scholar
- Boyce JM, Potter-Bynoe G, Chenevert C, King T: Environmental contamination due to methicillin-resistant Staphylococcus aureus (MRSA): possible infection control implications. Infect Control Hosp Epidemiol. 1997, 18: 622-627. 10.1086/647686.View ArticlePubMedGoogle Scholar
- Eckstein BC, Adams DA, Eckstein EC, Rao A, Sethi AK, Yadavalli GK, Donskey CJ: Reduction of Clostridium difficile and vancomycin-resistant Enterococcus contamination of environmental surfaces after an intervention to improve cleaning methods. BMC Infect Dis. 2007, 7: 61-10.1186/1471-2334-7-61.View ArticlePubMedPubMed CentralGoogle Scholar
- Hayden MK, Bonten JM, Blom DW, Lyle EA, van de Vijver D, Weinstein RA: Reduction in acquisition of vancomycin-resistant Enterococcus after enforcement of routine environmental cleaning measures. Clin Infect Dis. 2006, 42: 1552-60. 10.1086/503845.View ArticlePubMedGoogle Scholar
- Dumford DM, Nerandzic MM, Eckstein BC, Donskey CJ: What is on that keyboard? Detecting hidden environmental reservoirs of Clostridium difficile during an outbreak associated with North American pulsed-field gel electrophoresis type 1 strains. Am J Infect Control. 2009, 37: 15-9. 10.1016/j.ajic.2008.07.009.View ArticlePubMedGoogle Scholar
- Gerding DN, Muto CA, Owens RC: Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008, 46: 43-9. 10.1086/521861.View ArticleGoogle Scholar
- Hacek DM, Ogle AM, Fisher A, Robicsek A, Peterson LR: Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. Am J Infect Control. 2010, 38: 350-3. 10.1016/j.ajic.2009.11.003.View ArticlePubMedGoogle Scholar
- Carling PC, Parry MF, Bruno-Murtha LA, Dick B: Improving environmental hygiene in 27 intensive care units to decrease multidrug-resistant bacterial transmission. Crit Care Med. 2010, 38: 1212-4. 10.1097/CCM.0b013e3181d1ab3a.View ArticleGoogle Scholar
- Nerandzic MM, Cadnum JL, Pultz MJ, Donskey CJ: Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms. BMC Infect Dis. 2010, 10: 197-10.1186/1471-2334-10-197.View ArticlePubMedPubMed CentralGoogle Scholar
- Conner-Kerr TA, Sullivan PK, Gaillard J, Jones RM: The effects of ultraviolet radiation on antibiotic-resistant bacteria in vitro. Ostomy Wound Manage. 1998, 44: 50-6.PubMedGoogle Scholar
- Setlow P: Spores of Bacillus subtilis: their resistance to and killing by radiation, heat and chemicals. J Appl Microbiol. 2006, 101: 514-25. 10.1111/j.1365-2672.2005.02736.x.View ArticlePubMedGoogle Scholar
- Owens MU, Deal DR, Shoemaker MO, Knudson GB, Meszaros JE, Deal JL: High-dose ultraviolet C light inactivates spores of Bacillus subtilis var. niger and Bacillus anthracis Sterne on non-reflective surfaces. Appl Biosafety. 2005, 10: 240-247.View ArticleGoogle Scholar
- Becker MM, Wang Z: Origin of ultraviolet damage in DNA. J Mol Biol. 1989, 210: 429-38. 10.1016/0022-2836(89)90120-4.View ArticlePubMedGoogle Scholar
- Glendenin LE: Determination of the energy of beta particles and photons by absorption. Nucleonics. 1948, 2: 12-32.PubMedGoogle Scholar
- Takebe H, Jagger J: Action spectrum for growth delay induced in Escherichia coli B/r by far-ultraviolet radiation. J Bacteriol. 1969, 98: 677-82.PubMedPubMed CentralGoogle Scholar
- Duncan CL, Strong DH: Improved medium for sporulation of Clostridium perfringens. Appl Microbiol. 1968, 16: 82-9.PubMedPubMed CentralGoogle Scholar
- Nerandzic MM, Donskey CJ: Effective and reduced-cost modified selective medium for isolation of Clostridium difficile. J Clin Microbiol. 2009, 47: 397-400. 10.1128/JCM.01591-08.View ArticlePubMedGoogle Scholar
- Code of Federal Regulations Title 21 developed by the United States Food and Drug Administration. [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=801.415], Accessed 10 January 2012
- Jump RL, Pultz MJ, Donskey CJ: Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?. Antimicrob Agents Chemother. 2007, 51: 2883-7. 10.1128/AAC.01443-06.View ArticlePubMedPubMed CentralGoogle Scholar
- Barbut F, Menuet D, Verachten M, Girou E: Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for reduction of Clostridium difficile spores. Infect Control Hosp Epidemiol. 2009, 30: 507-14. 10.1086/597232.View ArticlePubMedGoogle Scholar
- Boyce JM, Havill NL, Otter JA, McDonald LC, Adams NM, Cooper T, Thompson A, Wiggs L, Killgore G, Tauman A, Noble-Wang J: Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol. 2008, 29: 723-729. 10.1086/589906.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/12/120/prepub